The National Patient Safety Alerting Committee issued a National Patient Safety Alert titled “Shortage of alteplase and tenecteplase injections” – NatPSA/2022/006/DHSC on 3rd August 2022. There will be supply constraints facing alteplase for the remainder of 2022 and tenecteplase injections will go out of stock in the coming months. At present the situation is expected to improve in early 2023. Alteplase must be reserved for thrombolysis of acute stroke. Click on the guideline below for alternatives in non-stroke indications:

Printable version of this page

Alteplase Trustwide Rapid Guideline.pdf Department: Pharmacy PDF, 499.7 KB, 5 pages